Company: CDLX
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001666071-25-000126
Chunk: 185

Company: Cardlytics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 8
Chunk 185
---
 January 18, 2023, our Board of Directors approved an amendment to the 2022 Inducement Plan to reserve an additional 350,000 shares of our common stock. On July 13, 2023, our Board of Directors approved an amendment to the 2022 Inducement Plan to reserve an additional 800,000 shares of our common stock. On November 6, 2024, our board of directors approved an amendment to the 2022 Inducement Plan to reserve an additional 2,500,000 shares of our common stock. As of June 30, 2025, there were 2,545,749 shares available under the 2022 Inducement Plan. 

19

The following table summarizes the allocation of stock-based compensation in the condensed consolidated statements of operations (in thousands): Three Months EndedJune 30,Six Months EndedJune 30, 2025202420252024Delivery costs$464 $721 $1,001 $1,364 Sales and marketing expense1,072 2,903 3,150 6,044 Research and development expense3,165 4,633 5,939 8,583 General and administrative expense2,800 4,387 6,105 7,638 Total stock-based compensation expense$7,501 $12,644 $16,195 $23,629 During the six months ended June 30, 2025 and 2024, we capitalized $1.9 million and $2.5 million of stock-based compensation expense for software development, respectively.Restricted Stock UnitsWe grant restricted stock units ("RSUs") to certain employees and our non-employee directors. The following table summarizes changes in RSUs, inclusive of performance-based RSUs:Shares(in thousands)Weighted-Average Grant Date Fair ValueWeighted-Average Remaining Contractual Term (in years)Unamortized Compensation Costs(in thousands)Unvested — December 31, 20244,507 $13.20 1.20$43,710 Granted4,969 2.19 Vested(1,475)14.40 Forfeited(736)13.99 Unvested — June 30, 20257,265 $5.56 0.98$26,740 During the six months ended June 30, 2025, we granted 4,969